Tryp Therapeutics Files Amended Financial Statements for the Six Months Ended February 29, 2024
Kelowna, British Columbia--(Newsfile Corp. - May 17, 2024) - Tryp Therapeutics, Inc. (CSE: TRYP) ("Tryp" or the "Company") announces, that it has filed amended financial statements for the six months ended February 29, 2024 (the "Financial Statements"), along with the corresponding Management Discussion & Analysis (the "MD&A"). The amendments to the financial statements resulted from a review of the financial statements conducted in May 2024 by the Company's auditors.Amendments to the Financial Statements are summarized in the following table:
2024-05-17 5:30 PM EDT
Tryp Therapeutics reicht IND-Antrag für klinische Phase-2a-Studie bei Fibromyalgie ein
San Diego, California--(Newsfile Corp. - Donnerstag, 4. November 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" oder das "Unternehmen"), ein Pharmaunternehmen mit Fokus auf der Entwicklung von Psilocybin-basierten Verbindungen für Krankheiten mit ungedecktem medizinischem Bedarf, gab heute bekannt, dass es einen Antrages für ein neues Prüfpräparat ("IND") bei der US-amerikanischen Food and Drug Administration ("FDA)" zur Bewertung ihres klinischen Kandidaten TRP-8802 in einer klinischen Phase-2a-Studie eingereicht hat, die in Zusammenarbeit mit der University of Michigan die Sicherheit und vorläufige...
2021-11-04 11:02 AM EDT
Tryp Therapeutics to Participate in Wonderland: Miami on November 8
San Diego, California--(Newsfile Corp. - November 4, 2021) - - Nov. 4, 2021 - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today that the Company will participate in Wonderland: Miami, presented by Microdose, on November 8, 2021. The conference will take place on November 8-9, 2021 in Miami, Florida. Greg McKee, Chairman and CEO, will participate in a panel discussion entitled,...
2021-11-04 7:05 AM EDT
Tryp Therapeutics Submits IND Application for Phase 2a Clinical Trial in Fibromyalgia
San Diego, California--(Newsfile Corp. - November 2, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today that it has submitted an Investigational New Drug ("IND") application to the U.S. Food and Drug Administration ("FDA") to evaluate its clinical candidate, TRP-8802, in a Phase 2a clinical trial that investigates safety and preliminary effectiveness of psilocybin-assisted therapy among patients with fibromyalgia in collaboration...
2021-11-02 7:05 AM EDT
Tryp Therapeutics to Present at 15th Annual Pain Therapeutics Summit
San Diego, California--(Newsfile Corp. - October 26, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced that the Company will present at the 15th Annual Pain Therapeutics Summit on November 1, 2021 at 12:15 p.m. EDT.The virtual conference will take place on November 1-3, 2021. Greg McKee, Chairman and CEO, will provide an overview of the Company followed by a live...
2021-10-26 7:05 AM EDT
Tryp Therapeutics Reports Clinical Hold on Proposed Phase 2a Study in Eating Disorders
San Diego, California--(Newsfile Corp. - October 20, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced that the U.S. Food and Drug Administration ("FDA") has placed a clinical hold on the Company's Phase 2a study for eating disorders that includes binge eating disorder and hypothalamic obesity. The notification from the FDA did not provide a reason for the clinical hold...
2021-10-20 7:00 PM EDT
Tryp Therapeutics Announces Inclusion in AdvisorShares Psychedelics ETF
San Diego, California--(Newsfile Corp. - October 14, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today its inclusion in the AdvisorShares Psychedelics ETF (the "Fund"), currently trading under the ticker symbol "PSIL" on the NYSE Arca exchange.The Fund is actively trading and focuses on companies that devote a majority of assets to psychedelic drug development. The Fund was launched in September of this year...
2021-10-14 7:05 AM EDT
Tryp Therapeutics to Present at the KSCA Psychedelics Virtual Investor Conference
San Diego, California--(Newsfile Corp. - October 12, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a pharmaceutical company developing psilocybin-based compounds for diseases with unmet medical needs, announced today that it will present at the KCSA Psychedelics Virtual Investor Conference on October 14, 2021 at 3:00 p.m. EDT.The conference will be held virtually on October 13-14, 2021. Luke Hayes, Chief Financial Officer, will provide a live overview of Tryp's activities and elaborate on how the Company...
2021-10-12 7:15 AM EDT
Tryp Therapeutics Announces Collaboration with Researchers at the University of Wisconsin-Madison
San Diego, California--(Newsfile Corp. - October 7, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today a collaboration with Paul Hutson, PharmD and Christopher Nicholas, PhD to support clinical pharmacology studies for the Company's proprietary drug product, TRP-8803.Dr. Hutson and Dr. Nicholas will serve as Investigators on a clinical pharmacology study to evaluate the safety and pharmacokinetics of TRP-8803 in healthy,...
2021-10-07 7:05 AM EDT
Tryp Therapeutics stellt IND-Antrag auf klinische Studie der Phase 2a zu Essstörungen
San Diego, California--(Newsfile Corp. - Mittwoch, 22. September 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp"), ein Pharmaunternehmen mit Fokus auf der Entwicklung von Psilocybin-basierten Verbindungen für Krankheiten mit ungedecktem medizinischem Bedarf, gab heute seine Einreichung eines Investigational New Drug (" IND ")-Antrags bei der US-amerikanischen Food and Drug Administration (FDA) bekannt. Dabei soll sein klinischer Kandidat TRP-8802 in einer Studie der Phase 2a zur Behandlung von Patient*innen mit Essstörungen evaluiert werden.Die Studie wird in Zusammenarbeit mit Dr. Jennifer...
2021-09-22 2:30 PM EDT
Tryp Therapeutics Submits IND Application for Phase 2a Clinical Trial in Eating Disorders
San Diego, California--(Newsfile Corp. - September 22, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today that it has submitted an Investigational New Drug ("IND") application to the U.S. Food and Drug Administration ("FDA") to evaluate its clinical candidate, TRP-8802, in a Phase 2a study for the treatment of patients with eating disorders.The trial is being conducted with Jennifer Miller, M.D., from the...
2021-09-22 7:05 AM EDT
Tryp Therapeutics to Present at Oppenheimer Fall Healthcare Summit
San Diego, California--(Newsfile Corp. - September 16, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today that it will present virtually at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit.The conference will be held virtually on September 20-23, 2021. Greg McKee, Chairman and CEO of Tryp, will provide an overview of the business and its pipeline including Tryp's Psilocybin-For-Neuropsychiatric Disorders (PFNTM) program for...
2021-09-16 7:05 AM EDT
CORRECTION FROM SOURCE: Tryp Therapeutics to Present at H.C. Wainwright Global Investment Conference
A correction from Tryp Therapeutics Inc. is being issued for the news release disseminated earlier today. The correction relates to an error in the presentation date and the disclosure of stock option grants. The presentation will be available on-demand beginning September 13, 2021 at 7:00 a.m. EDT. No other material changes were required in the body of the release.San Diego, California--(Newsfile Corp. - September 1, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp"), a pharmaceutical company focused on developing...
2021-09-01 10:01 AM EDT
Tryp Therapeutics to Present at H.C. Wainwright Annual Global Investment Conference
San Diego, California--(Newsfile Corp. - September 1, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, announced today that it will present at the H.C. Wainwright Annual Global Investment Conference.The conference will be held virtually on September 13-15, 2021. Greg McKee, Chairman and CEO of Tryp, will provide an overview of the business and its pipeline including Tryp's Psilocybin-For-Neuropsychiatric Disorders (PFNTM) program...
2021-09-01 7:05 AM EDT
Tryp Therapeutics Completes Psychotherapy Training for Phase 2a Study at the University of Florida
San Diego, California--(Newsfile Corp. - August 24, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today it has completed the training of psychotherapists for its upcoming Phase 2a clinical trial using synthetic psilocybin in combination with psychotherapy for overeating disorders. The training was conducted by Fluence, which is led by researchers and psychotherapists with direct experience in psychedelic clinical trials...
2021-08-24 7:05 AM EDT
Tryp Therapeutics Appoints Dennis Langer, M.D., J.D. as Senior Advisor
San Diego, California--(Newsfile Corp. - August 18, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today the appointment of Dennis Langer, M.D., J.D., as Senior Advisor to the Company.Dr. Langer has been a Director, Co-Founder, and CEO of various public and private biotechnology, specialty pharmaceutical, and diagnostic companies. He previously served as Senior Vice President of Research and Development at...
2021-08-18 7:05 AM EDT
Tryp Therapeutics Partners with Calvert Labs to Conduct Exploratory Studies for Proprietary Psilocybin Formulations
San Diego, California--(Newsfile Corp. - August 10, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, announced today an agreement with Calvert Labs to design and execute exploratory studies related to Tryp's Psilocybin-for-Neuropsychiatric Disorders (PFNTM) program.Calvert Labs, an Altasciences company, has a proven track record of executing FDA-approved studies across a broad range of the
2021-08-10 7:05 AM EDT
Tryp Therapeutics to Present at Canaccord Genuity Annual Growth Conference
San Diego, California--(Newsfile Corp. - August 3, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, announced today that it will present at the Canaccord Genuity Virtual Growth Conference.The conference will be held virtually on August 10-12, 2021. Greg McKee, Chairman and CEO of Tryp, will provide an overview of the business and its pipeline including Tryp's Psilocybin-For-Neuropsychiatric Disorders (PFN™) program for...
2021-08-03 7:05 AM EDT
Tryp Therapeutics Announces Q3 2021 Financial Results
San Diego, California--(Newsfile Corp. - July 28, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, announced today its interim financial results for the three and nine month period ended May 31, 2021. Complete financial statements along with related management discussion and analysis can be found in the System for Electronic Document Analysis and Retrieval, the electronic filing system...
2021-07-28 11:19 PM EDT
Tryp Therapeutics Appoints Robin Carhart-Harris, Ph.D. as SAB Chairman and Adds Daniel Clauw, M.D. as Scientific Advisor
San Diego, California--(Newsfile Corp. - July 26, 2021) - Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, announced today the appointment of Robin Carhart-Harris, Ph.D. as Chairman of its Scientific Advisory Board ("SAB") and Daniel Clauw, M.D. as a new member of the SAB.Dr. Carhart-Harris initially joined Tryp's SAB in February 2021 and has since been instrumental in advising the Company through the...
2021-07-26 9:43 AM EDT